Carregant...
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer
RET receptor tyrosine kinase (RTK) acts as an ontogenetic driver in several human malignancies, including papillary and medullary thyroid carcinoma, lung adenocarcinoma, colorectal carcinoma, Spitzoid neoplasms, salivary gland carcinoma and chronic myeloproliferative disorders, secondary to as diver...
Guardat en:
| Publicat a: | Best Pract Res Clin Endocrinol Metab |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5624797/ https://ncbi.nlm.nih.gov/pubmed/28911727 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.beem.2017.04.013 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|